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Summary.-An antigenic activity in pleural effusions of patients with squamous-cell
carcinoma ofthe lung has been prepared inhighly purified form by a5-step fractiona-
tion scheme. The purified substance, designated LuCA (lung cancer antigen), was
assessed during the course of the fractionation procedure by a radioimmunometric
assay carried out with specific soluble reagents. Sensitive saturation-binding assays
showed no or only weak uptake of the 1251-labelled antigen preparation by a panel of
antisera specific for known bronchogenic tumour markers, and for normal human
serum proteins. The preparation appeared to contain lung-tumour-associated
antigens, one of them probably distinct for squamous-cell carcinomas. The antigen
fraction consists of acid-soluble glycoproteins, and was demonstrated by SDS-
polyacrylamide gel electrophoresis as a single band in the mol. wt region of 43,000.
The gel-filtration elution volume appeared to indicate the occurrence of the antigenic
activity in multiples of this smaller unit. Pilot radioimmunoassays performed with
LuCA and an absorbed specific antiserum suggest the possible suitability of the
marker preparation for screening lung-cancer patients.
THE ISOLATION of soluble tumour-asso-
ciated antigens from lung tumour tissue
has recently been attempted by several
laboratories. The degree of antigenic and
cancer specificity was usually assessed by
immunodiffusion, immunoelectrophoresis,
or immunofluorescence, using antisera
from which antibodies to contaminants
had been removed by absorption. Many of
the preparations were not considered to be
distinct for tumour tissue or restricted
to lung tumours (Yachi et al., 1968;
Watson et al., 1975; Granlund & Ritts,
1976; Veltri et al., 1977; Bell et al., 1979;
Kempner et al., 1979) whereas others
were found at abnormally high concentra-
tion in extracts from lung tumours when
compared with those from normal lungs
(Louis et al., 1973; Frost et al., 1975;
Akeson, 1977). Frost et al. (1975) reported
an antigen with a mol. wt of 40,000 which
was heat and acid stable to a certain
extent and showed cationic mobility. The
antigen found by Braatz et al. (1978) had
a mol. wt of 77,000 by sedimentation
coefficient and a subunit of 42,000 by
SDS-polyacrylamide gel electrophoresis.
Only a few preparations to date have
been tested in radioimmunoassays for lung
cancer antigens (cf. Herberman, 1979).
One of us has described a semi-purified
glycoprotein with tumour-associated
characteristics (Wolf, 1978) which has
now been highly purified and used as
labelled antigen in radioimmunoassays for
the screening of patients' sera. In the
following, we present the purification pro-
cedure of this antigen, and results from
discrimination and specificity experiments
as well as from radioimmunoassays.
MATERIALS AND METHODS
Pleural effusions and patients' sera.-
Pleural effusions withdrawn by sterile punc-
ture were obtained from Lainz Hospital,
Vienna. Cells were removed by centrifuga-
tion, and the clear supernatant fluid was
stored at -20TC until use. Sera from malig-A. WOLF, M. MICKSCHE AND H. BAUER
nant patients and from healthy individuals
were also obtained by courtesy of Lainz
Hospital.
Production of antisera.-Fifteen rabbits
were injected with various materials: (a) with
minced tissue from normal lungs removed at
the time of a postmortem examination;
(b) with crude or purified fractions prepared
from pleural exudates of patients with
squamous-cell carcinoma of the lung, desig-
nated "specific antisera"; (c) with a fraction
comparable to (b) but derived from normal
human serum. In the case of solid material,
packed volumes of 0-2 to 0 5 ml were in-
jected, first i.m. then i.v., and finally i.d., at
weekly intervals. The animals were bled 6
weeks after the initial injection, and bled out
shortly thereafter when the antibody titre
was satisfactory. In the case of soluble frac-
tions, 20-200 ,ug protein (depending on the
availability of material), emulsified in
Freund's Complete Adjuvant, was injected
i.d. at 3 sites on the animal's flanks. The in-
jections were repeated 4 weeks later with
Freund's Incomplete Adjuvant, and the
animals were bled 6 weeks after the start of
immunization. If the resulting antiserum
showed a titre after absorption, injections
were repeated at intervals of one month.
Saturation-binding assays demonstrated that
the titre of absorbed specific antisera in-
creased gradually with the purification stage
of the preparation used for immunization.
Commercial antisera.-Twelve antisera
were purchased from either Dako-Immuno-
globulins, Copenhagen, or from Nordic Im-
munology, Holland (details in Table III).
Absorption of antisera.-Small amounts of
antisera were incubated in equal volumes,
first with cross-linked normal human serum
(Avrameas & Ternynck, 1969) for 15 min
at room temperature, and after thorough
shaking for a further 15 min at 4°C. The same
procedure was used for the absorption with
normal lung tissue.
Ion exchange chromatography.-A pleural
effusion containing 20 mg protein per ml
was applied to a column (15*0 x16 cm) of
DEAE-Sephacel (Pharmacia) equilibrated
with Tris/HC1 buffer (01M, pH 6.5). Elution
was carried out in steps, using initially the
same buffer and subsequently adding NaCl of
increasing molarity from 0dIM to 0-5M. Peak
fractions were pooled, dialysed against phos-
phate-buffered saline (O15M NaCl in phos-
phate buffer, O0O1M, pH 7.2) and concen-
trated with polyethylene glycol 20,000. These
and all further chromatographic manipula-
tions were carried out at 4°C.
Affinity chromatography.-Two ml of the
active DEAE fraction containing between
15 and 50 mg protein was applied to a
column (12-0 x I 0 cm) of concanavalin A-
Sepharose (Pharmacia) equilibrated with
phosphate-buffered saline (PBS). Elution of
the bound material was accomplished by
a-methyl-D-glucopyranoside (50 mm), and
after dialysis in PBS and concentration a
volume of this fraction, containing 2-4 mg
protein, was applied to a column (5.0 x I 0
cm) of wheat-germ lectin-Sepharose (Pharm-
acia), equilibrated with PBS. The bound pro-
tein was eluted by N-acetyl-D-glucosamine
(100 mg/ml) in PBS. Fractions were pooled,
dialysed, and concentrated.
Gel-filtration chromatography.-For a separ-
ation, 1-2 ml (containing 1-2 mg protein of
the material eluted by glucosamine from the
wheat-germ lectin-Sepharose column) was
filtered by upward flow through a column
(100 0 x 1 0 cm) of Sephacryl S 300 Superfine
(Pharmacia), equilibrated with 0-4M NaCl in
phosphate buffer, pH 8-0, 0-05M. Elution was
carried out with the same buffered NaCl (flow
rate 15 ml/h). To a separation of unlabelled
fractions an amount of , 105 ct/min of a
1251I-labelled antigen preparation was added
as tracer. When radio-labelled material was
chromatographed a total of 10-15 x 106
counts per min was applied to the column.
Absorption of purified fractions.-This was
performed with a cross-linked anti-human-
serum antiserum. Small amounts of antigen
preparations (0.3-0.5 ml) were incubated at
equal volumes with the solidified antiserum
for 15 min in the cold. After centrifugations
the supernatant was further processed.
Preparation of 125I-antigen.-Labelling
with Na 1251 (Radiochemical Centre, Amer-
sham) was carried out using the Chloramine-T
method (Hunter, 1974) with slight modifica-
tions. Between 5 and 20 ,ug protein was
labelled at a time, and a small Sephadex G-15
column, equilibrated with PBS, was used to
separate the labelled protein from the free
125iodide. Peak fractions of labelled protein
(sp. act. 10-20 HCi/,ug protein) were further
purified on a Sephacryl S 300 column as
described above.
Saturation-binding assay.-This method,
measuring the rate ofantigen uptake by anti-
serum (Ratcliffe, 1974), was used to determine
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the titre of antisera, or to obtain a criterion
for pooling and assessing 1251-antigen frac-
tions. Tests were performed with PBS (pH
7.2) as diluent, but antiserum concentrations
of 1: 10,000 and less were made up in normal
rabbit serum diluted 1:20. For defining an
antiserum titre, 10 1ul (s8000 ets/min) of a
known labelled antigen fraction was pipetted
into conical plastic tubes (Sarstedt GmbH,
0 75 ml) which had been rinsed with 0.15%
bovine serum albumin (BSA). This was
followed by the addition of 50 ,ul of the
unknown antiserum at 3-fold serial dilutions
starting at the concentration 1:20. After
mixing, the tubes were counted in an Auto
Gamma Scintillation Spectrometer (Packard)
and left overnight at 4°C. Tests were set up
in duplicate, including background (BG)
tubes containing labelled antigen and PBS
only. Next day 100 pl goat anti-rabbit anti-
serum (second antibody) was added, and the
tubes were left for another 3 h at 4°C. They
were then centrifuged on an Eppendorf
Microfuge at 10,000 rev/min for 5 min in
order to separate the bound from the free
label. The supernatant was carefully removed
and the tubes counted again. To assess un-
known labelled fractions from column separa-
tions, and to determine the specificity of
LuCA preparations, the method was the same
except that known antisera were used. For
both purposes the percent of bound label
precipitated in the tube (B) was determined
for each tube from the original total label (T)
and from this the mean percentage of the
duplicate tubes was calculated. The rate of
uptake was then expressed as B/T (sample)
minus B/T (BG) =percentage uptake.
Monitoring the antigenic activity.-The
relative antigenic activity of unlabelled
chromatographic fractions was assessed by a
competitive radioimmunometric assay, meas-
uring the inhibition of radio-labelled antigen
uptake by an absorbed specific antiserum.
Unknown unlabelled fractions were serially
diluted in PBS (pH 7.2) and 10 ,u of each
dilution was pipetted into conical tubes
rinsed with BSA. Ten ,ul of a labelled antigen
( 8000 cts/min) was added, followed by
50 ,lI ofabsorbed specific antiserum diluted as
judged by titration curves. Control tubes
contained label, antiserum and PBS only.
After mixing, the tubes were incubated in the
cold for 72 h. All further manipulations were
carried out as described for the saturation-
binding assay. Tests were set up in duplicate
or triplicate, and for each sample dilution the
mean percentage uptake was calculated as
above. Inhibition was expressed as:
B/T (sample)
B/T (serum control) percentage inhibition
-B/T (BG)
Only those fractions which gave the greatest
inhibition were further processed. The sensi-
tivity limit of this assay as performed with
semi-purified reagents was 100 ng protein/ml.
An example ofmonitoring the activity during
the course of purification is given in Fig. 1.
Radioimmunoassay.-Essentially the same
technique was used as for the radioimmuno-
metric assay, except that a 20% solution of
polyethylene glycol 6000 was substituted for
the second antibody (Grudzinskas et al.,
1977). After standing at 4°C for 72 h and the
01
z
2
ol- I-
20
40
60
80
1lUU , I I
0Ye
I
[pg/m ]TI Ila Rb III
DEAE SEPHACEL CONA WGL
FRACTION POOLS OF COLUMNS
FiG. 1. Monitoring by radioimmunometric
assay. The fractions were eluted from
chromatographic columns in the course of
the purification of preparation A/66. Pools
II (a) and II (b) together constitute the
peak material eluted by 0-2M NaCl from a
DEAE-Sephacel column. Pools I and III
were eluted by 0IM NaCl and 0-4M NaCl
respectively. CON A=an absorbed fraction
of a Coneanavalin A-Sepharose column.
WGL=an absorbed fraction of a wheat-
germ lectin-Sepharose column. 0 fractions
assayed at 100 ,ug/ml; 0 Fractions assayed
at 10 ,ug/ml. The absorbed specific anti-
serum had been raised with Peak B material
(Fig. 3(a)) and was used in the assay
1:500 diluted in PBS (pH 7.2). The
labelled antigen corresponds to material
marked "Pool" inFig. 3(b).Notetherelative
increase in inhibitory activity with pro-
gressing purification of the fractions.
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addition of 150 jil of polyethylene glycol, the
samples were left at room temperature for
15 min, then centrifuged and processed as
described above.
Samples of patients' sera to be assayed
were extracted with perchloric acid (final
concentration 0-6M) for 30 min at 4°C,
centrifuged at 5000 rev/min and the super-
natant was used for the assay. Calculation of
results was carried out first as percentage
inhibition, and then read in protein concen-
tration from a standard curve.
SDS-polyacrylamide gel electrophoresis.-
Analytical electrophoretic experiments were
carried out using, in principle, the technique
of Channing & Stanbridge (1978) using slab
gels. A 7.5% running gel in Tris/HCl buffer
(pH 8.8) was polymerized by tetramethylene
diamine and ammonium persulphate. It con-
tained 0-1% sodium dodecyl sulphate (SDS).
A 4% stacking gel was prepared with SDS in
Tris/HCl buffer (pH 6.8). Electrophoresis
with a running buffer ofTris/glycine (pH 8.3)
containing 0.1% SDS, was performed at
120 V, 40 mA. Samples (- 20 ,ug for protein
staining) were prepared in PBS and contained
SDS and 2-mercaptoethanol. Protein staining
was carried out with Coomassie Blue. For
autoradiography a total of - 3 x 104 cts/min/
sample was applied to the gel. After electro-
phoresis the gel was covered with a thin
plastic foil and, without drying, exposed to a
Kodak X-Omat R film for 24 h using an
intensifying screen (Kodak) to enhance auto-
radiography. Mol. wt markers included cyto-
chrome C (12,000), ovalbumin (43,000),
human serum albumin (68,000), human IgG
purified by an affinity column of protein A-
Sepharose (160,000) and ferritin (550,000).
Markers were labelled with 1251 for auto-
radiography.
RESULTS
Preparation ofthe marker
Fig. 2 shows the essential stages of the
purification. The final preparation was
termed lung-carcinoma antigen (LuCA)
and represented less than 1/105 of the
protein in the starting material. The
iodinated fractions were only roughly
judged for protein by calculation from the
labelling efficiency, since the protein con-
tent was immeasurably low.
PLEURAL EFFUSION
Rtemoval ofcells anid lipoproteins,
Dialysis against 0O1iA Tris/HCI pH 6-5,
15 ml (20 mg protein/mi)
DEAE-SEPHA( E,
0-1i Tris/HCl, pH 6-5.
Elution stepwise witl il(lrasillg NaCi in Tris/HCI,
Dialysis against PBS (pH 72) concentrate(l by PEG,
Fraction elute(d at 0.2,r Na(l (150)
CONCANAVALIN A-SEPHAROSE
PBS (pH 7.2)
Absorbed material eltute(d Wittl A-metIl- V1)D-g1luCoside
(1%)
WHEAT-GERM LE(CTIN-SEIMHAROSE
PBS (pH 7.2)
Absorbed material elitte(1 with N-avet - I)-
glucosamine (0.50,,)
SEPHACRYL S 300 SU]P)ERFINETX
(seeFig. 3(a))
Phosphate buffer pH 8-0, 0-05:% NaCI,
Filtrationwith 125I-tracer
Peak B (001 0)
125I.labelled absore by antiserum
to nol-rmal hiuman seruim
SEPHACRYL S 300
(seeFig. 3 (b)) 1251-labelled
"Pool" (0.002%)
SEPHACRYL S 300
(seeFig. 3 (e))
Peak F "LuCA"
(0.001%)
FIG. 2.-Flow diagram of the antigen puri-
fication scheme. The recovery of specific
material is given in parentheses as percent
of the protein content in the starting
material. Protein estimates were performed
by the Folin-Ciocalteus phenol method.
PEG=polyethylene glycol 20,000.
Details of the ion-exchange and affinity
columns have previously been given
(Wolf, 1978). Briefly, the most active anti-
genic material was found in the frac-
tion eluted by 0-2M NaCl from DEAE-
Sephacel, and in the fractions found by
both Con A and wheat-germ lectin-
Sepharose.
The relevant sections ofthegel-filtration
profiles from 3 consecutive Sephacryl
S-300 columns are depicted in Fig. 3. The
antigenic characteristics of the 3 protein
peaks [A], [B] and [C] (Fig. 3a) are shown
in Table I. The specific antigen resided
chiefly in Peak B as judged by both the
radioimmunometric and the saturation-
binding assay, whereas the main com-
ponent of Peak C appeared to be xl-acid
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FIG. 3. Sections of 3 Sephacryl S 300 gel-filtration profiles. Fractions were collected in 0-5ml volumes
(unlabelled material) and in 0-3ml volumes (labelled material). (a) Protein profile of a fraction
absorbed by and eluted from wheat-germ lectin-Sepharose. (b) 1251-profile of re-chromatographed
labelled Peak B material. (c) 1251-profile of Peak B material labelled after absorption with anti-
serum to normal human serum and then re-chromatographed. Nos 1-7 indicate single fractions
used in discrimination assays (Table II). LuCA =most purified lung-cancer-specific antigenic
material. CPM= ct/min.
TABLE I.-Antigenic discrimination of
fraction pools of a preparative Sephacryl
S 300 column (Fig. 3a) shown by com-
petitive radioimmunometric assay and by
saturation-binding assay
Radio- Saturation-binding assay
immuno- (% 125I-antigen uptake)
metric by antiserum to
assay
(% Specific
inhibition pleural-
Fraction at 100 ,ug effusion acl-Acid
pool protein/ml) antigen glycoprotein
Peak A 0 NT* NT*
B 80 70 (atl:5000) 0 (at 1:300)
C 40 15 (at 1: 500) 80 (atl:5000)
* Not tested. In parentheses; dilutions of antisera.
glycoprotein. When Peak B material was
labelled and re-chromatographed on Seph-
acryl (Fig. 3b) the specific antigenic
activity was found in the ascending part
ofPeak D. Since on this column it did not
clearly separate from the total peak, an
additional purification step was intro-
duced. Concentrated unlabelled Peak B
material was submitted to absorption with
an antiserum to normal human serum. It
was then iodinated and, by re-chromato-
graphy, separated clearly into 3 peaks
(Fig. 3c). Single fractions of these peaks
were tested in saturation-binding assays
with 4 different antisera, as shown in
Table II. The results indicated that Peak E
contained normal lung proteins, whereas
the intermediate Peak F was made up of
the pertinent antigenic material showing
a high specific activity, and being slightly
contaminated by substances of the ad-
jacent peaks. Peak G proved to consist
chiefly of normal serum proteins, in-
cluding small amounts ofthe specific lung-
cancer material. Fractions ofPeak F were
TABLE II.-Antigenic discrimination of single fractions from Sephacryl S 300 column by
saturation assay with 4 antisera diluted 1:10,000*
Antiserum to
Pleural effusion fraction
(xi-Acid glycoprotein
Normal human serum proteins
Normal human lung
% Maximal uptake of numbered 125I-fractions (Fig. 3(c))
Fraction No.: 1 2 3 4 5 6 7
Peak E Peak F Peak G
0
0
0
70
50 85
NT 20
NT 22
NT 15
30 20 NTt
0 NT 40
0 59 NT
NT NT 10
10
NT
NT
10
* The specific antiserum was used absorbed, the 3 other antisera unabsorbed.
t Not tested.
20
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iominated
iochemical
igen frac-
nitted to
A 91,
pooled as indicated and der
LuCA (lung-cancer antigen).
Molecular weight and degree of b
purity of the antigenic substance
Labelled and unlabelled anti
tions were concurrently subn
SDS-polyacrylamide electrophor
the experiment the slab gel wa:
halves which were then either
autoradiographed. It may be
from Fig. 4 that the absorption,
a b c d e f
LuCA
FIG. 4.-SDS electrophoresis in polyacryla-
mide gel. a-d, Samples stained with Coo-
massie blue; e-h, Autoradiographs of
labelled fractions (3 x 104 cts/min/sample);
a, h=human serum albumin; b, g=oval-
bumin; c=Peak B material (Fig. 3(a)) not
absorbed; d=Peak B material absorbed
withantiserum tonormalhumanserum; e =
Peak F material (Fig. 3(c)) designated
"LuCA"; f=Peak G material (Fig. 3(c))
found to be chiefly (xi-acid glycoprotein.
serum to normal human serum, removed
contaminants rather effectively, though
not completely, from the unlabelled anti-
gen preparation. On the other hand, the
labelled LuCA sample appears to be
homogeneous. Both labelled and un-
labelled LuCA samples formed a band in
a position close to ovalbumin thus ex-
hibiting, under the given reducing con-
ditions, a mol. wt of - 43,000. By gel
filtration, however, both preparations
appeared in fractions eluting from the
column before human serum albumin
suggesting a mol. wt > 68,000. There was
no difference by electrophoresis in the
position ofLuCA and al1-acid glycoprotein,
though from gel columns the 2 substances
clearly eluted in different but partly over-
lapping peaks (cf. Fig. 3c and Table II).
TABLE III.-Saturation binding assays
with antisera* to known bronchogenic
tumour markers or normal serum com-
ponents
'esis. Alter Antiserum
s cut into (not absorbed, diluted in PBS) raised to
gtained or Carcinoembryonic antigen (DAKO)t
gathered ,u-Chains (DAKO)
with anti- (xi-acidglycoprotein (DAKO)
Human albumin (DAKO)
Ferritin (NORDIC)
| 2-microglobulin (DAKO)
(X2-macroglobulin (DAKO)
P Pregnancy specific Pi-glycoprotein
(DAKO)
Lactoferrin (NORDIC)
|o-foetoprotein (NORDIC)
Human foetal proteins (NORDIC)
Human al-antichymotrypsin (DAKO)
h l -Normal humanlung
g h Normal human serum glycoprotein
Specific pleural-effusion antigen
(not absorbed)
Specific pleural-effusion antigen
(absorbed)
Titre (zero
or last
(ilution
showing
> 10%
uptake
of LuCA)
1:60
1:180
1:20
1:180
0
0
1:320
1:100
0
U
0
1:100
1:320
1:100
1: 20,000
1: 5000
* All antisera produced in the rabbit, apart from
that to human serum, which was produced in the pig.
t Commercial firms from which purchased.
Relationship ofLuCA to known markers and
normal serum components
Since there are several nonspecific
markers of bronchogenic cancers (cf.
review Coombes et al., 1978) the cross-
reactivity of LuCA was checked by
saturation binding assays with a panel of
14 antisera. Table III shows that antisera
to the known markers ferritin, lactoferrin,
and /32-microglobulin, did not take up
LuCA at all. Four other antisera directed
to a,-acid glycoprotein, carcinoembryonic
antigen (CEA), al-antichymotrypsin, and
pregnancy-specific 1i-glycoprotein ex-
hibited low titres of 1:20, 1:60, 1:100 and
1:100 respectively. LuCA does not appear
to be one of these markers, but it may
react nonspecifically with some antisera
at a low level. Similar observations were
made when antisera raised to normal lung
tissue or to normal serum components
were assayed. The highest titre obtained
was 1: 320 by anti-normal lung serum and
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anti-Ac2-macroglobulin serum. However,
the titre ofthe absorbed specific antiserum
was 1: 5000 when diluted in PBS, thus
exhibiting a discrimination factor of more
than 15.
Estimation of specific LuCA in serum
samples by radioimmunoassay
Assays were performed with a LuCA
preparation as labelled antigen, a Peak B
preparation as standard, and an absorbed
antiserum which had been raised with
Peak B fractions. This antiserum ex-
hibited a maximal LuCA uptake of 80%,
and was used in the present assays at
1: 50,000 diluted in 20% normal rabbit
serum.
In order to estimate the antigen content
of serum samples, a standard dose-
response curve was produced with serial
dilutions of Peak B material. Fig. 5 shows
that the assay has a lower limit of - 10 ng/
ml, and a working range of up to 5 ,ug/
40
- 20I
U)
10-
ml. Estimates above 400 ng/ml have a
relatively wide scatter.
Untreated test sera frequently gave
paradoxical results showing low, or nc
inhibition of label uptake when used un-
diluted, and increasing inhibition when
serially diluted. As this pointed to an
interfering factor in whole serum, samples
were extracted with perchloric acid, which
leaves a certain type of glycoprotein in
solution while precipitating the bulk of
normal proteins (Hakim, 1980). After
incubation the samples were cleared by
centrifugation, and the supernatant was
dialysed for 36 h against PBS (pH 7.8)
with 2 changes of the buffer. For assays
used the supernatant samples were used,
either non-diluted or diluted 1:10. As a
routine each assay series included several
dilutions of a standard preparation. The
5000 *
5000 00 a
0 0
1000 0 0
.
500
0
E
c
100
J
50
10*
0.003 0.016 0.08 0.4 2 10
LuCA ug/ml (protein)
FIG. 5. Standard (lose-response curve. It w%as
performed with LuCA as labelledl antigen,
Peak B fractions as standard, and an
antiserum raised1 witlh Peak B fractions
and absorbed with normal hiuman lung
tissue an(l cross-linke(d normal hutman
serum.
* I
10 0 000.00 00000 000
LUNG CARCINOMAS
SQUAMOUS CELL ADENO OAT
(metast.) (local CELL
*::::
NORMAL C
HUMAN T
SERA
OTHER
TUMOURS
FIG. 6. Quantitative determination of lung-
cancer-associate(l antigen(s) in sera by
ra(lioimmunoassay. The working range of
the assay is marked in accorclance with the
stai(lard curve. Sera ofpatients an(l normal
in(lividuals were assayedl. Eacll black circle
represents the mean of duplicate tubes.
li
. . . . .
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scatter of d(iplicate tubes of the unknown
samples was similar to that shown in Fig. 5.
Fig. 6 shows the outcome of experi-
ments with patients' and normal human
sera. In accordance with the standard
curve the limits within which the assay
yielded meaningful results have been
marked on the ordinate. The number of
acntigen estimates was too small for a cut-
off to be made for the marker level in
normal sera, and for analysing the figures
all sera falling within the assay limits have
been termed positive, and all sera below
the 10 ng/ml limit negative.
The percentage ofpositive sera appeared
particularly high (nearly 100%) in the
squtamous-cell-carcinoma group (meta-
static disease). In sera from the adeno and
oat-cell-type lung cancers (both also meta-
static) the percentage of positives was
found to be lower (730 and. 67% re-
spectively). However, only 25% of the
sera from early stages of squamous-cell
caircinomas (local disease) showed marker
levels within the sensitivity limits, as
compared with 5000 of the group with un-
related tumours (melanomas and breast
carcinomas both with metastases to the
lung). Most sera from normal individuals,
including 2 p1atients with bronchitis,
proved to be negative although a few
(fatlse?) positives were found among them.
No more sera from patients with non-
malignant lung diseases were avvailable at
the time of these assays.
1) ISCUSSION
The present marker preparation
"LuCA", isolated from malignant pleural
effusions of patients with squamous-cell
carcinoma of the lung by a 5-step purifica-
tion procedure, exhibited antigenic pro-
perties in common with fractions prepared
in a similar fashion from lung-tumour
extracts in our laboratory (cf. Wolf, 1978).
One of the preparations, furthermore, has
been shown to cross-react with antigens
that had been isolated from surgical
tumour specimens in other laboratories
(WVHO Study Group, in preparation).
To judge by its affinity to Con A and
wheat-germ lectin-Sepharose the main
component of the preparation appeared to
be a glycoprotein. It was demonstrated by
SDS-polyacrylamide electrophoresis as a
single band in the mol.-wt region of43,000.
Gel filtration, however, performed on
columns with PBS at pH 7 2, suggested a
mol. wt of 70-80,000 reflecting more
probably the native state of the antigen
molecule. It may well be possible that
the present and the previously reported
marker preparations represent a dimer, or
a polymer respectively, of the smaller
unit found under the reducing conditions
of the electrophoretic experiments.
Saturation-binding and immunometric
assays indicated that the preparation was
not a1-acid glycoprotein. This substance,
although occurring in large amounts in the
pleural effusions, has been almost com-
pletely separated from the specific anti-
genic material by gel filtration on Seph-
acryl 5 300. The antigenic activity, more-
over, did not appear to be one of a number
of other known bronchogenic cancer
markers. It was shown not to be ferritin,
32-microglobulin or lactoferrin. Antisera
to CEA, al-antichymotrypsin, and preg-
nancy-specific fli-glycoprotein were only
weakly cross-reactive. On the other hand,
a partial relationship to normal serum
components was noticeable, inidicating
that the preparation was not free of con-
taminants. But in the labelled LuCA in
high dilutions, as for example in radio-
immunoassays involving only picogram
quantities, such impurities may be negli-
gible as shown by autoradiographs.
It cannot be established at present
whether the main component of LuCA is
a genuine neoantigen expressed on the
surface or in the cytoplasm of the tumour
cell, or whether it is a product induced by
the spreading malignant growth. In any
case, in radioimmunoassays LuCA seems
to be preferentially replaced by substances
in lung-cancer sera, but not in normal sera.
The presented radioimmunoassays are
pilot experiments on a small scale. They
allow only preliminary conclusions about
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the usefulness of the developed test. The
assay system responds particularly well to
sera from patients with squamous-cell
carcinoma of the lung which appears to
prove a certain degree of specificity. But
the evidence from assays with sera from
other histological types of lung cancer
suggest that there may be several antigens
involved in the system, one possibly
distinct for squamous-cell carcinomas, and
others perhaps common to various histo-
logical types of lung cancer. To judge, on
the other hand, by the different antigen
contents in sera from early and late stages
of squamous-cell carcinoma, and from the
cross-reactivity of sera from patients with
unrelated metastatic tumours, one might
even speculate that the assay system
recognizes an antigen which is character-
istic for lung metastases of various origin.
But the data suggest that a LuCA-like
substance occurs in primary lesions too,
though probably at a low level.
In some patients the antigen concentra-
tion in the serum was found to have fallen
appreciably after surgery (results un-
published) and assays are now in progress
to follow up such fluctuations in a greater
number of sera and in relation to the
clinical status of the patient. This may
then provide further information on the
suitability of the marker preparation for
screening purposes.
The authors wish to thank Mr P. Breit for the
photographic work, and Mr V. Teichmann for help-
ing to raise the antisera.
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